Proliferative activity as an adjunct in the diagnosis of prostatic adenocarcinoma

A. F. Morey, B. Britton, G. E. Deshon, L. H. Kimura, M. L. Dresner, T. W. Crain

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Sixty-nine men underwent transrectal ultrasound-directed biopsy of the prostate. One biopsy core from each side of each gland was sent for DNA flow cytometric testing (138 total specimens). Results were correlated with findings from standard hematoxylin and eosin staining of other cores. Twelve patients (17.4%) had biopsies with histopathologic evidence of prostatic carcinoma. Of 57 patients (82.6%) with benign biopsies, two had stage A prostate adenocarcinoma noted on subsequent transurethral resection. Proliferative activity was calculated from DNA histograms by adding the percentage of nuclei in the proliferative (S and G2/M) phases of the cell- division cycle. Mean proliferative activity for the malignant group (19.08) was significantly higher (p < 0.001) than that of the benign group (13.43). Inflammation was associated with elevated proliferative activity scores among benign glands. Proliferative activity is an objective, easily obtainable indicator of the biological activity of a population of cells which, when elevated, may suggest a need for repeat biopsy in patients with otherwise normal prostate biopsies. Flow cytometry may have value as a complement to standard histologic analysis of transrectal core biopsies in the diagnosis of prostate cancer.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalMilitary Medicine
Volume159
Issue number2
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Proliferative activity as an adjunct in the diagnosis of prostatic adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Morey, A. F., Britton, B., Deshon, G. E., Kimura, L. H., Dresner, M. L., & Crain, T. W. (1994). Proliferative activity as an adjunct in the diagnosis of prostatic adenocarcinoma. Military Medicine, 159(2), 91-94.